Smoking and Nicotine

Combustible tobacco is the single largest preventable-mortality lever in modern medicine, and much of the harm is reversible after quitting — the earlier the better. Vapes and oral nicotine pouches drop the smoke but keep their own cardiovascular and addiction risks, while a striking low-dose-nicotine longevity signal so far exists only in mice.

The smoking question split into two questions once non-combustible nicotine products spread: what does the smoke do, and what does the nicotine do? For combustible cigarettes the answer is unambiguous and the largest preventable-mortality lever in modern medicine. For e-cigarettes and oral pouches, harm reduction relative to smoking is real, but "less than cigarettes" is a low bar — they carry their own endothelial, addiction, and (for pouches) cardiovascular signals. For isolated low-dose nicotine in the transdermal-patch format, the cardiovascular data from short-term quitting trials show no clear excess of serious events, though they are imprecise, the acute cognitive effects are small but consistent, and recent mouse work hints at an NAD+/SIRT1 longevity pathway that has not been validated in humans.

What the evidence says

Strong:

  • Tobacco is the leading preventable cause of death worldwide: it kills more than 7 million people a year, including over 1.6 million non-smokers exposed to second-hand smoke[1].
  • Current smokers die at roughly three times the rate of never-smokers and lose more than a decade of life; about half to two-thirds of persistent smokers are eventually killed by the habit[2][3].
  • Quitting before about age 40 avoids roughly 90% of the excess risk of death from continued smoking; the earlier the quit, the larger the recovered life expectancy[4][5].
  • For quitting itself, varenicline and cytisine are the most effective single medications, and combination nicotine-replacement therapy and nicotine e-cigarettes rank among the most effective options; the evidence is high-certainty[6].
  • Cumulative lifetime smoking exposure (pack-years, parental smoking, youth initiation) accelerates the GrimAge clock in older adults and predicts all-cause mortality on top of that[7].
  • Smokers have slightly shorter blood-cell telomeres than never-smokers on average (pooled analysis of 30 studies); a weak link with pack-years appeared in five studies, and most data are single snapshots rather than measured rates of shortening[8].

Moderate:

  • Quitting is followed by slightly slower cognitive decline: in about 9,400 smokers aged 40–89 across 12 countries, memory and verbal fluency declined a little more slowly in the six years after quitting than in matched people who kept smoking, with no clear difference by age at quitting[9]. In a US cohort of about 13,000 adults aged 52–75, people who had quit 9 or more years before the study began had no higher dementia risk than never-smokers, while recent quitters and current smokers had higher risk[10]. Both are observational.
  • In 41 double-blind lab studies of healthy non-smokers and smokers who had not gone more than about two hours without nicotine, a dose of nicotine gave small-to-moderate gains in fine motor skill, alertness, attention speed, short-term memory and working-memory speed; working-memory accuracy did not improve, and there were too few studies of self-control (inhibition) to tell[11].
  • Right after a vaping session, heart rate rises by about 1.4 beats per minute and blood pressure by about half a mm Hg, and blood markers of blood-vessel-lining activation and platelet stickiness go up[12]. Cohorts followed for about four years have not shown a clear rise in heart attacks, strokes or heart failure in people who only vape, but follow-up is short and events are few; people who both vape and smoke carry roughly smoking-level cardiovascular risk, so a switch has to be complete[13][14].
  • In randomised trials of nicotine replacement (about half comparing a nicotine patch with a placebo patch, mostly in smokers trying to quit), serious cardiovascular events such as heart attack, stroke and cardiovascular death were rare and not clearly more common than with placebo, but events were too few to rule out a modest risk, and the review was written in collaboration with a tobacco company[15]. A 2014 network meta-analysis found cardiovascular events overall about twice as common with nicotine replacement, mostly less serious ones, with no clear excess of major events[16].
  • A cross-sectional study of about 800 young Korean adults (under 40) found current smokers had about 2.4 times the odds of metabolic syndrome, with 2.6 times the odds of high triglycerides and 3 times the odds of low HDL cholesterol; former smokers did not have raised odds of metabolic syndrome[17].
  • Adolescent cotinine-confirmed second-hand smoke exposure associates with ~4.7× metabolic-syndrome odds[18]. Beyond metabolic effects, non-smokers exposed to second-hand smoke carry roughly 25–30% higher coronary-heart-disease risk and 20–30% higher lung-cancer risk, per the Surgeon General's syntheses[19]. The 2014 Surgeon General report adds stroke, with about 20–30% higher risk[20].
  • The cardiovascular risk profile of oral nicotine pouches (ZYN and competitors) is essentially unstudied long-term despite explosive growth — US unit sales rose several-hundred-fold between 2016 and 2020 — with sympathetic spikes documented but durable hemodynamic and addiction outcomes not[21][22]. The American Heart Association states plainly that no data exist on the cardiovascular or health risks of these products, and that this absence of data must not be read as evidence of safety[23].

Weak / preliminary:

  • A small study of 8 long-term heavy smokers and 8 non-smokers in their 60s found slower muscle-protein building in smokers, plus higher activity of genes that block muscle growth (myostatin, about 33% higher) and break muscle down (MAFbx, about 45% higher), a plausible route to faster muscle loss, though muscle loss itself was not measured[24].
  • One small reanalysis of existing tissue samples (lung tissue mostly from lung-cancer surgery patients) found smokers' lung tissue looked about 4 years older on an epigenetic clock than non-smokers'; airway cells showed a similar but non-significant gap, and cheek and oesophagus cells showed none. Ex-smokers' airway cells were not distinguishable from non-smokers' while their lung tissue still was, a hint, not proof, that some damage persists[25].
  • Low-dose nicotine (2 µg/mL in drinking water) restored NAMPT activity, raised NAD+, preserved motor and exploratory behavior, and stabilized telomere-associated TPP1/RAP1 ratios in male mice treated from 6 to 12 months of age (young adult to middle age; many measurements used three animals per group, and lifespan was not tested) — via SIRT1-mediated deacetylation of NAMPT, independent of nicotinic acetylcholine receptors[26]. Mouse data only; no human trial of nicotine as an NAD+ booster yet.
  • Exercise studies of nicotine are few and small; most performance measures show no effect, with isolated gains and losses about equally common[27].

Caution:

  • Adolescent nicotine exposure permanently reduces hippocampal CA1 dendritic length and predisposes to adult depression and learning deficits in rodent models, mirroring elevated relapse and cognitive-deficit signals in humans who started smoking young[28].
  • In a small study funded by the World Anti-Doping Agency (WADA), 10 trained male cyclists, each tested at 18 °C and 30 °C, wore a nicotine patch: it reduced forearm blood flow and raised core temperature slightly (about 0.2 °C) during exercise without improving performance. The researchers concluded that nicotine raises heat-illness risk when exercise is combined with heat stress, though no heat illness was measured (Weak / preliminary)[29].
  • Smoking in pregnancy raises the risk of fetal growth restriction, low birth weight and perinatal death. Obstetric guidance is to advise stopping every tobacco product, e-cigarettes included, and to offer counselling, behavioural support and medication[30]. In trials with pregnant smokers, nicotine replacement showed no clear harm to babies, though its benefit for quitting is uncertain (low-certainty evidence)[31].
  • High-pH oral pouches drive fast free-base nicotine delivery; addiction liability is high and the long-term cardiovascular profile is unknown. US bench testing of 37 brands found ~1.3–6.1 mg nicotine per pouch at pH ~6.9–10.1, with a large unprotonated (free-base) fraction — the alkaline chemistry that maximises absorption[32]. (Higher per-pouch figures cited elsewhere reflect broader global-market surveys.)

Mortality, years of life lost, and the cessation dividend

The mechanistic story below — clocks, telomeres, muscle, metabolism — is how smoking ages cells. The population data are how much it kills, and they are the highest-graded evidence in the whole topic (Strong; large prospective cohorts with hard endpoints). The magnitude, consistency, dose-response and biological plausibility make the causal inference about as robust as anything in modifiable-risk epidemiology, residual socioeconomic confounding notwithstanding.

The half-century British Doctors Study — 34,439 male doctors followed from 1951, the cohort that first established the smoking–lung-cancer link prospectively — found that persistent cigarette smokers lost about 10 years of life versus never-smokers, and that between half and two-thirds of persistent smokers were eventually killed by the habit: about half of those born in 1900–1909, and about two-thirds of those born in the 1920s, who had smoked cigarettes more intensively from early adult life[33]. A large contemporary US cohort put the all-cause death rate among current smokers at about three times that of never-smokers (hazard ratio ~3.0 in women and ~2.8 in men — that is, roughly triple the risk), again with more than a decade of life expectancy lost[34]. The Million Women Study reached the same place from the other side of the Atlantic: about two-thirds of the deaths of smokers in their 50s, 60s and 70s were caused by smoking[35]. These modern relative risks are higher than older textbook figures, because the full lifetime hazard of cigarettes only became visible once whole cohorts had smoked from adolescence to old age[36].

The cessation dividend is steep and age-graded. In the same US cohort, adults who quit at 25–34, 35–44, or 45–54 years of age gained back about 10, 9, and 6 years of life respectively, and quitting before about age 40 avoided roughly 90% of the excess risk of death from continued smoking[37]. Women who stopped before ~40 carried only about a tenth of the excess mortality of continuing smokers, and those who stopped before ~30 almost none of it[38]. This is the specific, motivating rebuttal to the "I've smoked too long for it to matter" framing — it is never too late to gain, and it is far better to quit early. A 2024 pooled analysis of about 1.5 million adults aged 20 to 79 in four countries found that quitting at any age was linked to longer survival: lower death risk showed up within 3 years of quitting, even for people who quit in their 40s and 50s, and people who had been off cigarettes for 10 years or more had survival close to that of never-smokers[39]. In the British Doctors Study, men who quit at 60 still gained about 3 years of life[40]. Both are observational.

How to quit: what the trials show

The page's mandate is what works and how strong the evidence is, so the practical question — how do you actually quit — deserves the same treatment. The cessation evidence here is among the highest-graded in the whole topic (Strong). A Cochrane network meta-analysis pooling the pharmacological and e-cigarette options found high-certainty evidence that varenicline (a nicotinic partial agonist) and cytisine (a plant-derived partial agonist) roughly double quit rates versus placebo, and that combination nicotine-replacement therapy (patch plus a fast-acting form) and nicotine e-cigarettes rank among the most effective options available[41]. Varenicline alone increases the chance of quitting by roughly 2.3-fold over placebo across dozens of trials (high certainty), and cytisine works about as well: the two head-to-head trials found no clear difference, with perhaps a small edge for varenicline[42]. Two large placebo-controlled US trials of cytisine (about 800 adult daily smokers each, funded by the manufacturer) have since confirmed that it helps and is well tolerated: on a 12-week course, about 1 in 5 people stayed off cigarettes continuously from week 9 to week 24, against about 1 in 20 on placebo[43][44].

The definitive head-to-head trial, EAGLES, randomised 8,144 smokers across 16 countries to varenicline, bupropion, nicotine patch, or placebo. End-of-treatment continuous abstinence was 33.5% on varenicline, 23.4% on the patch, 22.6% on bupropion, and 12.5% on placebo — every active treatment beat placebo, and varenicline beat both the patch and bupropion. Crucially, the trial found no significant excess of neuropsychiatric adverse events from varenicline or bupropion relative to patch or placebo, which led the US Food and Drug Administration to remove the varenicline/bupropion neuropsychiatric boxed warning in 2016[45]. (EAGLES was funded by Pfizer and GlaxoSmithKline, which manufacture varenicline and bupropion — worth holding in mind.)

Cellular and epigenetic aging

Smoking is among the most consistent accelerators of biological-aging biomarkers ever measured (Strong for the associations; Weak / preliminary for the partial-reversal-on-cessation claim). The signal shows up across:

  • Epigenetic clocks. In one small reanalysis, smokers' lung tissue ran about 4 years older on an epigenetic clock than non-smokers'; airway, cheek and oesophagus cells showed no significant gap. GrimAge and DunedinPACE pick this up systemically; per-standard-deviation cotinine increments translate to ~1.4 years of GrimAge2 acceleration in the US National Health and Nutrition Examination Survey (NHANES), in adults aged 50–84[46] (see also environmental toxins). The single best-characterised smoking marker is hypomethylation at cg05575921 in the AHRR (aryl-hydrocarbon-receptor-repressor) gene, one of the strongest exposure–methylation associations known and linked to subclinical atherosclerosis; it moves back toward never-smoker levels the longer someone has been smoke-free, though some difference can persist for decades[47].
  • Telomere attrition. Smoking lowers expression of shelterin components (TRF2, POT1) and the catalytic telomerase subunit hTERT in blood and buccal samples, accelerating chromosomal-end degradation and replicative senescence.
  • Autophagy and SIRT1. Cigarette smoke extract suppresses SIRT1, activates PARP-1, and tips the airway and lung into pathological autophagic flux and senescence — the molecular substrate for chronic obstructive pulmonary disease (COPD).

In the small Wu et al. reanalysis, ex-smokers' airway cells were not distinguishable from never-smokers' while their lung tissue still was, a hint, not proof, that some damage persists after quitting[48]. The mortality data tell a similar story: the benefit of quitting accumulates over years and comes close to never-smoker survival, especially for adults who quit before midlife.

Cognition: the acute–chronic split

The neurological evidence is bimodal (Moderate for both halves). In laboratory tests, a single dose of nicotine gives small improvements in fine motor skill, alertness, reaction speed and short-term memory, in non-smokers and in smokers who have not gone more than about two hours without nicotine; working-memory speed improves but accuracy does not, and there were too few studies of self-control to tell[49]. Mechanism is straightforward — nicotinic acetylcholine receptor (nAChR) activation triggers dopamine, acetylcholine, and glutamate release across cortex and basal ganglia. There's a specificity caveat: nicotine narrows attention onto focal stimuli at the expense of peripheral-orienting flexibility, which is why heavy users describe both "lock-in" focus and missing things in their environment. Long-term daily use has not shown a lasting benefit: in a two-year trial of 348 people aged 55–90 with mild cognitive impairment who had not regularly used tobacco or nicotine in the past year, a daily nicotine patch (up to 21 mg) did not improve memory or overall clinical status compared with placebo (results posted on the trial registry, not yet published in a journal)[50].

Chronic combustible smoking does the opposite over years. High-resolution MRI of heavy smokers shows gray-matter atrophy in superior temporal gyrus, insula, precuneus, and posterior cingulate, extending into thalamus, putamen, and pallidum at higher exposure. Thalamic atrophy specifically correlates with the impulse-control failures that predict relapse — the brain physically loses the structure that supports quitting.

In three large ageing cohorts in England, continental Europe and the US, people who quit had slightly slower memory and verbal-fluency decline over the following six years than those who kept smoking[51]. In a separate US cohort, people who had quit about 9 or more years before the study began had no higher dementia risk than never-smokers, while recent quitters still had higher risk[52]. Both are observational studies. For brain health, quitting is one of several modifiable levers; see Dementia prevention.

Muscle and exercise

Smoking plausibly speeds muscle loss with age, but the direct evidence is thin (Weak). A small study of 8 long-term heavy smokers and 8 non-smokers in their 60s found slower muscle-protein building in smokers, plus about 33% higher activity of myostatin, a gene that blocks muscle growth, and about 45% higher activity of MAFbx, which breaks muscle down; muscle mass itself was not measured[53]. Nicotine alone contributes peripheral vasoconstriction that limits oxygen and amino-acid delivery to working muscle and slows recovery.

The ergogenic case for isolated nicotine in athletes is weaker than its popularity in elite sports would suggest. A review of the ten exercise studies available found that 12 of 16 performance measures showed no effect of nicotine; two improved (leg strength by about 6% in one small study of 9 men on 2 mg gum, endurance time by about 17% in another on a 7 mg patch) and two got worse. Nicotine is about as likely to hurt performance as to help it, and the studies are few and small[54]. The withdrawal window is also relevant: in the first 12–24 hours after cessation, attention and reaction time drop measurably; beyond 48 hours, a rebound improvement appears.

Two underappreciated cautions for athletes: in one small study nicotine reduced forearm blood flow and slightly raised core temperature during exercise, which its authors read as a heat-illness risk; and combining nicotine with a high-fat diet drives intramyocellular lipid accumulation and mitochondrial abnormalities in muscle that don't occur with the high-fat diet alone.

Metabolic effects

The metabolic picture is time-dependent (Moderate). The acute appetite-suppressing, weight-modulating effect of nicotine — long the marketing rationale for its non-medical use — comes from α-adrenoceptor-driven catecholamine release and a transient drop in fasting glucose. Chronically, the picture inverts: nicotine is toxic to pancreatic β-cells in animal models, drives insulin resistance, and predisposes to metabolic syndrome and type 2 diabetes in human cohorts. Quitting often brings weight gain: in three large US cohorts, people who had quit 2 to 6 years earlier had a somewhat higher diabetes risk than people who kept smoking; the excess peaked 5 to 7 years after quitting, was seen only in people who gained weight, and then faded. Even so, quitters' risk of dying from heart disease or from any cause still fell sharply, with or without weight gain[55]. The Fagerström-dependence score correlates linearly with the TyG insulin-resistance index — addiction severity tracks metabolic damage.

This is one of the reasons "vaping for weight loss" is a strictly worse trade than the alternative interventions discussed under Metabolic flexibility and the prescription GLP-1 receptor agonists.

Delivery systems: not interchangeable

Delivery vectorCardiovascularRespiratoryKey toxicants & risks
Combustible cigarettesSevere atherosclerosis, thrombosis, large MI/stroke riskIrreversible COPD, emphysema; linked to ~80% of US lung-cancer deaths[56]7,000+ chemicals incl. tar, CO, polycyclic aromatic hydrocarbons, cadmium
E-cigarettes / vapes (electronic nicotine-delivery systems, ENDS)Acute +1.4 bpm HR and ~0.5 mm Hg BP rise after vaping; raised endothelial-activation and platelet markers; no clear excess of heart attack or stroke in exclusive vapers so far (short follow-up); dual use about as risky as smokingReduced lung function; asthma odds ~1.3×; rare vaping-associated lung injury (EVALI) — traced to vitamin E acetate in illicit THC cartridges, not regulated nicotine e-liquidAldehydes (formaldehyde from coil-heated propylene glycol), heavy metals (Ni, Pb, Cr) from coils
Oral pouches (e.g., ZYN)Acute sympathetic spikes; long-term CV outcomes unstudiedNegligible direct respiratory loadHigh pH (~7–10) maximizes free-base bioavailability; ~1.3–6 mg nicotine/pouch in US bench testing; addiction-prone; trace nitrosamines possible
Transdermal patchTransient mild HR/BP rise; no clear excess of serious CV events in short-term cessation RCTs (imprecise); more minor CV eventsNoneSteady-state pharmacokinetics; used medically as a quitting aid

The "harm-reduction" hierarchy these data support: combustible >> ENDS ≥ pouches >> transdermal patch. None of this validates ENDS or pouches as long-term recreational products in healthy adults — the absence of decades of cohort data is doing a lot of the work for them, and the acute cardiovascular effects are real even though hard-outcome signals in exclusive vapers have not yet appeared.

A few named data points sharpen the continuum. The much-repeated claim that vaping is "95% less harmful than smoking" is not a measurement — it traces to a 2014 expert-judgment scoring exercise, amplified by a 2015 Public Health England review, and has been sharply criticised as a "factoid" resting on thin evidence and a partly non-transparent funding source[57][58]. Treat it as a contested estimate, not a fact. On the other side of the ledger, for smokers who are trying to quit, high-certainty evidence now shows nicotine e-cigarettes help more people quit than conventional nicotine-replacement therapy — the favourable half of the vaping story that sits alongside its cardiovascular risks (Strong for cessation efficacy)[59]. The 2026 update of that living review (80 trials) confirms the advantage over nicotine replacement at high certainty, with serious side effects rare in all trial arms[60]. EVALI, the 2019–2020 lung-injury outbreak, was overwhelmingly caused by vitamin E acetate added as a diluent to illicit THC cartridges — found in the lung-lavage fluid of 48 of 51 cases and none of the healthy controls — rather than being an intrinsic hazard of regulated nicotine e-liquid[61].

"Smokeless" is not one risk category — product chemistry drives most of the variance. Low-nitrosamine Swedish snus sits well below cigarettes but is not risk-free: a pooled analysis of eight Swedish cohorts of never-smoking men found that current exclusive snus users, compared with men who never used tobacco, had roughly 28% higher all-cause mortality and about 27% higher cardiovascular mortality, with a borderline rise in cancer deaths overall (about 12%); the risks grew with years of use but not with the amount used per week (Moderate)[62]. At the opposite end, high-nitrosamine smokeless products and areca-nut/betel-quid preparations (International Agency for Research on Cancer, IARC, Group 1 carcinogens, dominant across South-Central Asia) were estimated to cause roughly 120,000 oral cancers in 2022 — about 31% of the global total, overwhelmingly in low- and middle-income countries (Strong)[63].

The low-dose nicotine paradox

The most interesting recent finding is a mouse study that should not be over-interpreted (Weak / preliminary — single rodent study, no human data). Male mice given low-dose nicotine (2 µg/mL) in drinking water from 6 to 12 months of age (young adult to middle age; many measurements used three animals per group, and lifespan was not tested) showed:

  • Restored NAMPT activity in brain, liver, and pancreas;
  • Increased β-NMN (a direct NAD+ precursor) and systemic NAD+;
  • Preserved exploratory behavior and motor function characteristic of younger animals;
  • Suppressed pathological glucose hypermetabolism on FDG-PET;
  • Increased TPP1 and decreased RAP1 in tissues, stabilizing telomere-associated complexes.

The mechanism is specific: nicotine physically facilitates the binding of SIRT1 to NAMPT, allowing SIRT1 to deacetylate and activate NAMPT, which feeds back into the NAD+ salvage pathway. The action does not extend to SIRT1's other substrates (p53, NF-κB, PGC-1α) and is independent of the classical nicotinic acetylcholine receptors. In effect, the molecule may behave like a non-canonical NAD+ booster on a small subset of SIRT1 substrates.

What this is not, yet: a human longevity intervention. There is no human trial of low-dose nicotine for NAD+ repletion or epigenetic-clock deceleration. The mouse work and the reassuring but imprecise short-term cardiovascular data on nicotine patches together motivate cautious interest, not a recommendation. Anyone with a history of nicotine addiction should treat experimental low-dose use with extreme skepticism — addiction biology is unforgiving.

For the current generation of NAD+ interventions actually supported by human data, see Geroprotectors.

Practical guidance

  1. If you smoke combustibles, quitting is the single largest health intervention available to you. No other modifiable factor in this corpus has a comparable effect size on all-cause mortality — quitting by your mid-30s to mid-40s buys back most of a decade of life expectancy, and quitting before ~40 avoids roughly 90% of the excess death risk. That specific arithmetic, not vague reassurance, is the answer to "I've smoked too long for it to matter."
  2. Use the treatments that work. Varenicline or cytisine, combination nicotine-replacement therapy (patch plus a fast-acting form), or a nicotine e-cigarette used with a planned exit all substantially raise quit rates; varenicline and cytisine are the most effective single medications, and varenicline's neuropsychiatric safety concern was resolved by the EAGLES trial.
  3. Vapes are not "safe" — they're less bad than cigarettes. Defensible as a cessation tool with a planned exit. Not defensible as a long-term recreational habit, particularly in healthy adults with no smoking history.
  4. Oral nicotine pouches deserve more skepticism than they currently receive. High-pH formulations maximize absorption and addiction potential; the cardiovascular profile is essentially unstudied. The youth uptake curve is alarming.
  5. Nicotine is no help for building muscle. Smoking plausibly speeds age-related muscle loss, and nicotine has not reliably improved strength or endurance.
  6. Don't combine nicotine with hot-environment endurance exercise. The evidence is one small study, but heat illness is acute and the precaution costs nothing.
  7. Adolescent exposure is in a different category. Both human and animal data suggest the developing brain takes permanent structural hits from chronic nicotine. Vaping marketed to teenagers is a public-health failure, not a harm-reduction success.
  8. Low-dose nicotine as a longevity intervention is not yet evidence-based for humans. Watch the literature; do not act on mouse data.

What's overrated

  • "Vaping is safe." It's safer than combustible smoking. It is not without measurable cardiovascular and respiratory effects, and the long-cohort data are still arriving.
  • Nicotine as a sport-performance enhancer. Most performance measures show no effect, and isolated gains are matched by losses; a possible heat-stress risk.
  • Nicotine as an "NAD+ booster" in humans. Strong mouse signal; zero human longevity trials.
  • The historical claim that nicotine itself is comparable in harm to tobacco smoke. Combustion products do most of the cancer and cardiovascular damage; isolated nicotine has its own narrower risk profile.

Further reading

  • World Health Organization. Tobacco fact sheet. 2026.[64]
  • Doll R et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004.[65]
  • Jha P et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013.[66]
  • Pirie K et al. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 2013.[67]
  • Lindson N et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev 2023.[68]
  • Anthenelli RM et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES). Lancet 2016.[69]
  • Lindson N et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2026.[70]
  • Byhamre ML et al. Swedish snus use is associated with mortality: a pooled analysis of eight prospective studies. Int J Epidemiol 2021.[71]
  • Blount BC et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med 2020.[72]
  • Dennison Himmelfarb CR et al. Impact of smokeless oral nicotine products on cardiovascular disease: a policy statement from the American Heart Association. Circulation 2025.[73]
  • Wu X et al. Effect of tobacco smoking on the epigenetic age of human respiratory organs. Clin Epigenetics 2019.[74]
  • Klopack ET et al. Lifetime exposure to smoking, epigenetic aging, and morbidity and mortality in older adults. Clin Epigenetics 2022.[75]
  • Astuti Y et al. Cigarette smoking and telomere length: a systematic review of 84 studies and meta-analysis. Environ Res 2017.[76]
  • Petersen AM et al. Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle. Am J Physiol Endocrinol Metab 2007.[77]
  • Heishman SJ et al. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 2010.[78]
  • Mündel T. Nicotine: sporting friend or foe? Sports Med 2017.[79]
  • Yang L et al. Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity. Nat Commun 2023.[80]
  • ENDS health impact — umbrella review. 2025.[81]
  • Kim MM et al. A systematic review of RCTs to examine the risk of adverse cardiovascular events with nicotine use. Front Cardiovasc Med 2023 (tobacco-industry funded).[82]
  • Bloomberg M et al. Cognitive decline before and after mid-to-late-life smoking cessation: a longitudinal analysis of prospective cohort studies from 12 countries. Lancet Healthy Longev 2025.[83]

— § —